Revolution Medicines revenue and financials
$207.68Change from previous close: +0.50%Absolute change: +$1.04
Fiscal year ending in December. Sources and method on the page Methodology and sources.
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Total revenue | 0.0 | 0.0 | 11.6 | 35.4 | 29.4 | 43.0 | 50.0 | 20.2 |
| Cost of revenue | 987 | 592 | 419 | 253 | 187 | — | — | — |
| Gross profit | -987 | -592 | -408 | -218 | -158 | — | — | — |
| Selling, general and administrative | 195 | 97.3 | 68.1 | 40.6 | 30.5 | — | — | — |
| Research and development | 987 | 592 | 423 | 253 | 187 | 132 | 91.8 | 51.1 |
| Operating income | -1,182 | -690 | -487 | -258 | -188 | -111 | -54.1 | -40.3 |
| EBIT | -1,182 | -690 | -476 | -258 | -188 | — | — | — |
| EBITDA | -1,175 | -683 | -471 | -254 | -185 | — | — | — |
| Interest expense | 24.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 |
| Pre-tax income | -1,131 | -601 | -440 | -249 | -187 | — | — | — |
| Income tax | 0.0 | -0.8 | -3.5 | -0.4 | 0.0 | -0.4 | -4.4 | — |
| Net income | -1,131 | -600 | -436 | -249 | -187 | -108 | -47.7 | -41.8 |
| Net income to common shareholders | -1,131 | -600 | -436 | -249 | -187 | — | — | — |
| Basic EPS | -5.95 | -3.58 | -3.86 | -3.08 | -2.57 | -2.01 | — | — |
| Diluted EPS | -5.95 | -3.58 | -3.86 | -3.08 | -2.57 | -2.01 | — | — |
| Average shares (basic) | 190 | 168 | 113 | 80.6 | 72.8 | — | — | — |
| Average shares (diluted) | 190 | 168 | 113 | 80.6 | 72.8 | 54.9 | — | — |